Theravance is a place for advanced thinkers, people who thrive on using their minds and working with some of the industry's best to energize science.
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.
Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.
The key elements of our strategy are to:
Apply our expertise in multivalency to efficiently discover and develop superior medicines in areas of significant unmet medical need. Our drug discovery efforts are based on our expertise in multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. We believe that by applying our expertise in multivalency we can discover medicines that will be superior to many market-leading medicines by substantially improving potency, duration of action and/or selectivity.
Identify at least two structurally different product candidates in each therapeutic program whenever practicable. We believe that this can increase the likelihood of successfully bringing superior medicines to market.
Partner with pharmaceutical companies to accelerate development and commercialization of our product candidates. Our strategy is to seek collaborations with pharmaceutical companies to accelerate development and commercialization of our product candidate pipeline at the strategically appropriate time.
Leverage the extensive experience of our people. We have an experienced senior management team with many years of experience discovering, developing and commercializing new medicines with companies such as Bristol-Myers Squibb Company, Gilead Sciences, Merck & Co., and Pfizer.
Improve, expand and protect our technical capabilities. We have created a substantial body of know-how and trade secrets in the application of our multivalency approach to drug discovery. We believe this is a significant asset that distinguishes us from our competitors. We expect to continue to make substantial investments in multivalency and other technologies to maintain what we believe are our competitive advantages in drug discovery.